Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: Direct utility elicitation

Health and Quality of Life Outcomes

Volumn 6, Issue , 2008, Pages

  Briggs, Andrew ^a,b   Wild, Daine ^a   Lees, Michael ^a   Reaney, Matthew ^a   Dursun, Serdar ^c   Parry, David ^d   Mukherjee, Jayanti ^d  

^a ICON PLC   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; HYPERPROLACTINEMIA; INTERVIEW; MALE; QUALITY OF LIFE; RELAPSE; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; WEIGHT GAIN; MIDDLE AGED; PATHOPHYSIOLOGY; QUESTIONNAIRE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ENGLAND; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 58149343542     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-6-105     Document Type: Article

References (28)

1. The World Health Report, Mental Health: New understanding, new hope Geneva: World Health Organisation (WHO) 2001.
2. Lee TT Ziegler JK Sommi R Sugar C Mahmoud R Lenert LA Comparison of preferences for health outcomes in schizophrenia among stakeholder groups Journal of Psychiatric Research 2000, 34:201-210. 10.1016/ S0022-3956(00)00009-1 10867115
3. Sevy S Nathanson K Schlecter C Fulop G Contingency Valuation and Preferences of Health States Associated With Side Effects of Antipsychotic Medications in Schizophrenia Schizophrenia Bulletin 2001, 27(4):643-651. 11824490
4. Brixner DI Said Q Corey-Lisle PK Tuomari AV L'Italien GJ Stockdale W Oderda GM Naturalistic Impact of Second-Generation Antipsychotics on Weight Gain Annals of Pharmacotherapy 2006, 40:626-632. 10.1345/ aph.1G564 16569802
5. Koro CE Fedder DO L'Italien GJ Weiss SS Magder LS Kreyenbuhl J et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study BMJ 2002, 325:243. 117636 12153919 10.1136/ bmj.325.7358.243
6. Räsänen P Roine E Sintonen H Semberg-Konttinen V Ryynänen O-P Roine R Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review International Journal of Technology Assessment in Health Care 2006, 22(2):235-241. 10.1017/S0266462306051051 16571199
7. Voruganti LN Awad AG Oyewumi LK Cortese L Zirul S Dhawan R Assessing health utilities in schizophrenia. A feasibility study Pharmacoeconomics 2000, 17(3):273-286. 10.2165/00019053-200017030-00005 10947302
8. Brazier J Akehurst R Brennan A Dolan P Claxton K McCabe C O'Hagan A Sculpher MJ Tsuchyia A. Should patients have a greater role in valuing health states: Whose well-being is it anyway? Sheffield Health Economics Group Discussion Paper Series (Ref: 04/3) University of Sheffield 2004.
9. National Institute for Clinical Excellence (NICE) Guide to the methods of technology assessment London: NICE 2004.
10. EuroQoL Group EuroQoL: A new facility for the measurement of health related quality of life Health Policy 1990, 16:199-208. 10.1016/ 0168-8510(90)90421-9 10109801
11. Dolan P Modeling valuations for EuroQol health states Medical Care 1997, 35(11):1095-1108. 10.1097/00005650-199711000-00002 9366889
12. Willis GB Cognitive Interviewing: A "How To" Guide. From the short course "Reducing Survey Error through Research on the Cognitive and Decision Processes in Surveys," presented at the Meeting of the American Statistical Association 1999.
13. Cummins C Stevens A Kisely S The use of olanzapine as a first and second choice treatment in schizophrenia, West Midlands Development and Evaluation Committee Report, Wessex Institute for Health Research and Development 1998.
14. Glennie JL Pharmacoeconomic evaluations of clozapine in treatment resistant schizophrenia and risperidone in chronic schizophrenia Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
15. Risebrogh NA Lanctot KL Can patients with schizophrenia judge health related quality of life? Health state utility measurement in a sample of patients with stable schizophrenia Clinical Investment Medicine 1998:sUpplement-S17.
16. Lee TT Ziegler JK Sommi R Sugar C Mahmoud R Lenert LA Comparison of preferences for health outcomes in schizophrenia among stakeholder groups Journal of Psychiatric Research 2000, 34:201-210. 10.1016/ S0022-3956(00)00009-1 10867115
17. Revicki DA Shakespeare A Kind P Preferences for schizophrenia-related health states: A comparison of patients, caregivers and psychiatrists International Clinical Psychopharmacology 1996, 11:101-108. 10.1097/ 00004850-199611020-00004 8803647
18. Sevy S Nathanson K Schlecter C Fulop G Contingency Valuation and Preferences of Health States Associated With Side Effects of Antipsychotic Medications in Schizophrenia Schizophrenia Bulletin 2001, 27(4):643-651. 11824490
19. Awad AG Voruganti LN Cost-utility Analysis in Schizophrenia Journal of Clinical Psychiatry 1999, 60(suppl 3):22-26. 10073373
20. Kay SR Fiszbein A Opler LA The Positive and Negative Syndrome Scale for schizophrenia Schizophrenia Bulletin 1987, 13:261-276. 3616518
21. Cardinal Broadcast Two cases of schizophrenia. An illustrated lecture DVD 2004 http://www.mental-health.tv.
22. Torrance GW Feeny D Furlong W Visual Analog Scales: Do they have a role in the measurement of preferences for health states? Medical Decision Making 2001, 21:329-344. 10.1177/02729890122062622 11475389
23. Drummond MF O'Brien B Stoddart GL Torrance GW ed Cost-utility analysis Methods for the Economic Evaluation of Health Care Programmes Oxford: Oxford University Press 2; 1997.
24. Loewenstein G O'Donoghue T Rabin M Projection Bias In Predicting Future Utility The Quarterly Journal of Economics 2003, 118(4):1209-1248. 10.1162/003355303322552784
25. Ubel PA Loewenstein G Jepson C Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public Quality of Life Research 2003, 12:599-607. 10.1023/ A:1025119931010 14516169
26. Lysaker PH Buck KD Taylor AC Roe D Associations of metacognition and internalized stigma with quantitative assessments of self-experience in narratives of schizophrenia Psychiatry Res 157,(1-3):31-8. 2008 Jan 15 18023881
27. Bellack AS Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications Schizophr Bull 2006, 32(3):432-42. 10.1093/schbul/sbj044 16461575
28. Adams J Davey P Jackson D Croker V Aristides M Mullen K Montgomery W Using a community sample to derive utility values of schizophrenia treatment outcomes from a time trade-off methodology ISPOR 7th Annual International Meeting, 19-22 May, Arlington. Poster presentation 2002.